Operation Trailblazer: A Shift Toward Collaborative, Patient-Centered Clinical Development
Operation Trailblazer signals a new operating model for clinical trials
Operation Trailblazer is a multi-stakeholder initiative designed to accelerate clinical development through closer collaboration between regulators, sponsors, and research organizations. Announced by the U.S. Department of Health and human Services (HHS) on Wednesday, 22nd June, 20261, and aligned with the Association of Clinical Research Organizations (ACRO), the initiative reflects a growing emphasis on improving trial efficiency while maintaining regulatory rigor and patient safety. At its core, Operation Trailblazer signals a shift toward more coordinated, innovation-driven approaches to drug development—particularly in areas where speed and scientific precision are critical.
“Advancing clinical research requires bold collaboration. Initiatives like Operation Trailblazer are an important step forward in how our industry delivers innovation, and ultimately, more timely access to new treatments for patients. At its core, Operation Trailblazer reflects a shared commitment to accelerating clinical development, strengthening regulatory alignment, and ensuring that scientific breakthroughs translate more efficiently into real-world impact.”
- Cassandra S. Kennedy, Chief Quality, Regulatory Affairs, & Sustainability Officer
Where CROs are seeing early impact
Contract Research Organizations (CROs) play a critical role in Operation Trailblazer1. As the operational backbone of global clinical trials, CROs bring scale, experience, and innovation needed to execute complex studies, expand patient access, and uphold the highest standards of quality and compliance. Through ACRO (Association of Clinical Research Organizations), our industry continues to collaborate with policymakers, regulators, and sponsors to advance pragmatic solutions that improve trial efficiency while protecting patient safety and data integrity.
As Cassandra Kennedy, Fortrea’s Chief Quality and Regulatory Affairs Officer, shared: “Operation Trailblazer represents the kind of forward-thinking collaboration our industry needs—bringing together regulators, sponsors, and CROs to accelerate innovation without compromising the rigor and trust that patients depend on.”
The opportunity for early-phase development
At Fortrea, we see this impact most clearly in early-phase research—where speed, scientific rigor, and quality are paramount. Our clinical pharmacology and early development capabilities enable rapid study start-up, adaptive designs, and high-quality data generation that inform critical early decisions and set the trajectory for successful later-phase development. This is where innovation meets execution—and where initiatives like Operation Trailblazer can have outsized impact.
We are encouraged by the momentum behind this initiative and remain committed2—through ACRO and across our organizations—to helping shape a more agile, patient-centered clinical research ecosystem. Cassandra Kennedy, serves as the Chair of the ACRO Board of Directors, and actively guides the organization's efforts to work with global regulators on establishing safe frameworks for the use of artificial intelligence (AI) and data protection in clinical trials3.
Getting ahead of regulatory change with Fortrea
Fortrea’s Consulting group integrates regulatory strategy, intelligence, and execution across the full asset lifecycle—helping sponsors make confident decisions earlier and design development programs that stand up to regulatory and commercial scrutiny. Through continuous regulatory insight, regional understanding, and thoughtful use of advanced technology, we can help reduce risk, prevent re-work, and keep development on track.
Discuss how evolving initiatives like Operation Trailblazer may shape your development strategy. Our team can help you navigate early-phase design, regulatory alignment, and execution considerations in a rapidly shifting environment. Get in touch today.
References
- HHS Launches Unprecedented Department-Wide Effort to Restore American Leadership in Clinical Trials. https://www.hhs.gov/press-room/hhs-launches-clinical-trials-reform-initiative.html . Last updated 22.06.2026. Last accessed 24.06.2026
- ACRO announces 2026 Officers. https://www.acrohealth.org/2025/12/10/acro-announces-2026-officers-and-new-members/ . Last updated 10.12.2025. Last accessed 24.06.2026
- Incoming ACRO chair says CROs are influencing AI regulation development. https://www.bioxconomy.com/clinical-and-research/incoming-acro-chair-says-cros-are-influencing-ai-regulation-development . Last updated 16.12.2025. Last accessed 24.06.2026
FAQs
What is Operation Trailblazer?
Operation Trailblazer is an industry-led initiative promoting closer collaboration between regulators, sponsors, and CROs to improve clinical trial efficiency while maintaining safety and data integrity. It reflects a broader shift toward more integrated development models, where alignment across stakeholders is increasingly seen as a critical enabler of speed, quality, and patient impact. It was announced on Wednesday, 22nd June 2026 by the U.S. Department of Health and Human Services (HHS)1.
Why does Operation Trailblazer matter for sponsors?
Operation Trailblazer signals a move toward faster, more aligned development models, with greater emphasis on efficiency without reducing scientific or regulatory rigor1. In practice, this may require sponsors to reassess how early-phase decisions are made, how regulatory interactions are structured, and where operational agility can be built into development programs.
How will CROs contribute to Operation Trailblazer?
CROs are expected to play a central role by enabling scalable trial execution, improving patient access, and supporting regulatory alignment through industry collaboration frameworks such as ACRO. Their role is likely to expand beyond execution, contributing earlier in study design and helping sponsors translate innovation into operationally feasible and compliant trial strategies.